Javascript must be enabled to continue!
Making Agency Visible: Patient Perspectives on Engagement in Cardiovascular Research
View through CrossRef
Objectives: To examine how cardiovascular patients perceive and enact agency in research partnerships, including decision-making, communication, health literacy, and sustained engagement.Methods: This qualitative study involved semi-structured interviews with 14 patient partners who participated in a national Masterclass on cardiovascular research. The Masterclass was designed to strengthen patient capacity for research involvement through education, mentorship, and collaborative activities. Interview transcripts were analyzed thematically, guided by the Patient Agency in Research (PAIR) framework, which conceptualizes agency as intentional, self-reflective action expressed through individual, proxy, and collective modes.Results: Participants reported increased confidence, health research knowledge, and intentionality in their roles as research partners. They described navigating power imbalances, confronting tokenism, and advocating for more inclusive and responsive research cultures. Key findings included self-directed learning, empowerment, psychological safety, and the critical role of trust, respect, and transparent communication in fostering meaningful collaboration. Despite challenges, participants emphasized the value of structured support in helping them move from passive participants to active contributors.Conclusion: Agency is a core element of meaningful and sustained patient engagement in research. However, it does not arise automatically—it must be deliberately cultivated through educational interventions, inclusive practices, and ongoing relational support.Practice implications: Programs like the Masterclass can activate and strengthen patient agency, enabling individuals with lived experience to shape research in ways that are personally meaningful and scientifically impactful. By investing in patient capacity and fostering equitable research environments, institutions can move engagement beyond tokenism and toward partnerships that reshape the purpose—and the practice—of health research.
Title: Making Agency Visible: Patient Perspectives on Engagement in Cardiovascular Research
Description:
Objectives: To examine how cardiovascular patients perceive and enact agency in research partnerships, including decision-making, communication, health literacy, and sustained engagement.
Methods: This qualitative study involved semi-structured interviews with 14 patient partners who participated in a national Masterclass on cardiovascular research.
The Masterclass was designed to strengthen patient capacity for research involvement through education, mentorship, and collaborative activities.
Interview transcripts were analyzed thematically, guided by the Patient Agency in Research (PAIR) framework, which conceptualizes agency as intentional, self-reflective action expressed through individual, proxy, and collective modes.
Results: Participants reported increased confidence, health research knowledge, and intentionality in their roles as research partners.
They described navigating power imbalances, confronting tokenism, and advocating for more inclusive and responsive research cultures.
Key findings included self-directed learning, empowerment, psychological safety, and the critical role of trust, respect, and transparent communication in fostering meaningful collaboration.
Despite challenges, participants emphasized the value of structured support in helping them move from passive participants to active contributors.
Conclusion: Agency is a core element of meaningful and sustained patient engagement in research.
However, it does not arise automatically—it must be deliberately cultivated through educational interventions, inclusive practices, and ongoing relational support.
Practice implications: Programs like the Masterclass can activate and strengthen patient agency, enabling individuals with lived experience to shape research in ways that are personally meaningful and scientifically impactful.
By investing in patient capacity and fostering equitable research environments, institutions can move engagement beyond tokenism and toward partnerships that reshape the purpose—and the practice—of health research.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Piece by piece: Collaborative mosaic-making for inclusive policy development
Piece by piece: Collaborative mosaic-making for inclusive policy development
This report sets out the findings from one of four projects commissioned by Wellcome Policy Lab to pilot creative approaches to policy development. In this project, Scientia Script...
Cardiovascular Malformations Among Preterm Infants
Cardiovascular Malformations Among Preterm Infants
Objective. Preterm birth and cardiovascular malformations are the 2 most common causes of neonatal and infant death, but there are no published population-based reports on the rela...
Patient harm from cardiovascular medications
Patient harm from cardiovascular medications
Background
Medication harm can lead to hospital admission, prolonged hospital stay and poor patient outcomes. Reducing medication harm is a priority for healthc...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...

